Cargando…
Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients
BACKGROUND: Cardiovascular risk is increased in patients with chronic kidney disease (CKD). Fibroblast growth factor 23 (FGF23) has emerged as an important, independent predictor of outcome in CKD patients. High FGF23 may, however, be a reflection of renal tissue resistance to its actions, reflected...
Autores principales: | Bech, Anneke P., Bouma-de Krijger, Annet, van Zuilen, Arjan D., Bots, Michiel L., van den Brand, Jan A. J. G., Blankestijn, Peter J., Wetzels, Jack F. M., Vervloet, Marc G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4498282/ https://www.ncbi.nlm.nih.gov/pubmed/25700931 http://dx.doi.org/10.1007/s40620-015-0178-0 |
Ejemplares similares
-
Abdominal aortic calcification in patients with CKD
por: Peeters, Mieke J., et al.
Publicado: (2016) -
Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort
por: Vervloet, Marc G, et al.
Publicado: (2012) -
Fibroblast growth factor 23: are we ready to use it in clinical practice?
por: Bouma-de Krijger, Annet, et al.
Publicado: (2020) -
FGF23 and Phosphate–Cardiovascular Toxins in CKD
por: Vogt, Isabel, et al.
Publicado: (2019) -
Change in FGF23 concentration over time and its association with all-cause mortality in patients treated with haemodialysis or haemodiafiltration
por: Bouma-de Krijger, Annet, et al.
Publicado: (2020)